摘要:
The present invention relates to an aceclofenac-containing soft capsule formulation having improved stability and the preparation thereof, and more particularly to a method of preparing a soft capsule by dissolving or dispersing aceclofenac, which is unstable in an aqueous solution, in oil or a mixture of oils. The aceclofenac-containing soft capsule contains an aceclofenac-containing liquid composition prepared by mixing and solubilizing aceclofenac, oil and a suspending agent. The soft capsule can maintain stability for 3 years or more and has improved active ingredient dissolution compared to existing soft capsules, thus increasing the bioavailability of the active ingredient.
摘要:
The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a phar¬ maceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.
摘要:
The present invention relates to a controlled-release preparation administered orally once a day that exhibits an optimum pharmacological clinical effect, featuring two-layer tablets, dual tablets and multilayered tablets having a fast-release layer comprising aceclofenac, a water-soluble additive, a non-soluble additive, a solubilizer, a disintegrator and a filler, and a slow-release layer comprising aceclofenac, a slow-release base, a disintegrator, a binder, a filler, a fluidizer, a solubilizer and a lubricant.
摘要:
The present invention relatestoa cont rolled-re lease niacin formulation. In particular, the present invention relates to a controlled-release niacin formulation, comprising niacin; hydroxypropyl methylcellulose; and a carboxyvinyl polymer, in which the carboxyvinyl polymer and hydroxypropyl methylcellulose are contained in a predetermined weight ratio, and to a preparation method thereof. The controlled-release niacin formulation according to the present invention maintains its matrix shape until completion of release, and also release pattern without fluctuation for a desired time period, unlike other formulations. Inparticular, since niacin formulations are used for long-term treatment of hyperlipidemia, the controlled-release niacin formulation of the present invention, capable of maintaining effective blood concentration and high stability for a long period of time, is very useful.
摘要:
The present invention relates to oral dosage forms containing acetaminophen. More particularly, the present invention relates to oral dosage forms containing acetaminophen as a model drug, polymer base, disintegrants and lubricant, where the water-soluble additives further are contained in the said preparations. The dosage forms of the present invention are formulated to various formulations such as tablet, compressed pellet, granule and capsule. Upon exposure to the various dissolution media, the oral dosage forms of the present invention absorb water and form a gel structure, showing rapidly release of 50 % drug within a few minutes like a commercial two-layered tablet followed by the extended release thereafter. The release rate of drug is mainly governed by the swelling and erosion rate of the polymer base together with additives incorporated in matrix tablet. Unlike the two-layered commercial tablet, the new heterodisperse and single-layered HPMC matrix tablet could be easily prepared by using conventional tablet machine. The dosage forms also provide an economical and unique preparation method.
摘要:
The present invention relates to a composition for the controlled-release of drugs. More particularly, the composition for the controlled-release of drugs according to the present invention expands the capacity for the controlled-release of a matrix-type polymer for controlled-release via a carbomer in which said polymer for controlled-release forms a basic frame and in which sol-gel transition occurs in accordance with a pH level. The composition of the present invention is characterized in that it comprises: a solubilizing agent for the event the drug to be released is highly insoluble, and a disintegrating agent for sufficient initial release. The composition for the controlled-release of drugs according to the present invention uses a carbomer which maintains the controlled-release of conventional matrix structures having polymers for controlled-release and which has sol-gel transition properties, thus preventing a sudden release of a drug caused by a collapse of the matrix structure during a late stage of elution. In addition, the composition of the present invention uses a solubilizing agent to solve the problem of a highly insoluble drug failing to dissolve even after being released, and also uses a disintegrating agent to improve the speed of the initial release, which is the limiting factor in controlled-release preparations.
摘要:
The present invention relates to a biocompatible contrast agent and a method of its preparation. More particularly, the present invention relates to a multifunctional contrast agent manufactured by prepairing a novel polysuccinimide-based polymer by introducing an alkanolamine group to the main group of the pioysuccinimide in addition to a biocompatible hydrophilic group, which improves bioavailability, and a hydrophobic group, which enables to maintain the form of stable nanoparticles during the formation of nano particles for a long period of time and to encapsulate a hydrophobic anticancer agent.
摘要:
Disclosed herein are single-layer and double-layer tablets, which release aceclofenac in a controlledmanner so as to achieve ideal drug release close to a straight line. Also, the tablets promote drug absorption in the stomach by controlling pH, contain aceclofenac with improved stability and haveboth immediate-release properties and sustained-release properties. Specifically, provided is an aceclofenac sustained-release tablet which is composed of an immediate-release layer containing aceclofenac, a water-soluble additive, a pH-controlling agent, a disintegrant, a filler and a lubricant and of a sustained-release layer containing aceclofenac, a release-controlling polymer, an oil-soluble surfactant, a filler and a lubricant, wherein the pH-controlling agent is sodium hydrogen carbonate, and the release-controlling polymer is a mixture of hydroxypropylmethylcellulose and carbomer.
摘要:
The present invention relates to a controlled release formulation containing niacin. More specifically, the present invention relates to a controlled release-niacin formulation and a preparation method thereof, wherein the controlled release-niacin formulation comprises niacin, hydroxypropyl methylcellulose, carboxyvinyl polymers, additives, disintegrants, and lubricants, wherein the carboxyvinyl polymer and hydroxypropyl methylcellulose are included so that the weight ratio of the carboxyvinyl polymer: HPMC is 1:1 - 1:100. In addition, the present invention provides a combination formulation further containing an HMG-CoA reductase inhibitor in the controlled release-niacin formulation and a preparation method thereof.
摘要:
The present invention relates to a controlled release formulation containing niacin. More specifically, the present invention relates to a controlled release-niacin formulation and a preparation method thereof, wherein the controlled release-niacin formulation comprises niacin, hydroxypropyl methylcellulose, carboxyvinyl polymers, additives, disintegrants, and lubricants, wherein the carboxyvinyl polymer and hydroxypropyl methylcellulose are included so that the weight ratio of the carboxyvinyl polymer: HPMC is 1:1 - 1:100. In addition, the present invention provides a combination formulation further containing an HMG-CoA reductase inhibitor in the controlled release-niacin formulation and a preparation method thereof.